BICYCLE THERAPEUTICS PLC

For the period ended Sep 30, 2026. Filed Oct 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 29, 2026

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)


· · Three Months Ended · · Nine Months Ended
· · September 30, · · September 30,
· · 2026 · · 2025 · · 2026 · · 2025
Collaboration revenue	$34,057	$11,734	$35,573	$24,631
Operating expenses:
Research and development	33,422	58,426	123,483	188,513
General and administrative	14,112	18,859	45,608	58,475
Total operating expenses	47,534	77,285	169,091	246,988
Loss from operations	(13,477)	(65,551)	(133,518)	(222,357)
Other income (expense):
Interest and other income	4,213	6,700	13,450	22,587
Interest expense	(45)	(44)	(137)	(149)
Total other income, net	4,168	6,656	13,313	22,438
Net loss before income tax provision	(9,309)	(58,895)	(120,205)	(199,919)
Provision for (benefit from) income taxes	1,169	205	1,431	(1,113)
Net loss	$(10,478)	$(59,100)	$(121,636)	$(198,806)
Net loss per share, basic and diluted	$(0.15)	$(0.85)	$(1.74)	$(2.87)
Weighted average ordinary shares outstanding, basic and diluted	69,979,934	69,303,746	69,823,830	69,251,291

Comprehensive loss:
Net loss	$(10,478)	$(59,100)	$(121,636)	$(198,806)
Other comprehensive income (loss):
Foreign currency translation adjustment	79	(108)	(1,832)	(3,590)
Total comprehensive loss	$(10,399)	$(59,208)	$(123,468)	$(202,396)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.